Next Phase Newsletter

A healthcare-focused venture investment fund is backed by a core investment team with members all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The firm’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A clinical stage biopharmaceutical company headquartered in China with additional offices throughout USA and China is dedicated to antibody-based biotherapeutics discovery, research, development, and manufacturing. The firm is actively looking for early-stage opportunities to supplement their pipeline, and can engage in various types of partnerships including in-licensing, equity investment, and M&A. The firm is open to global opportunities.

The firm is primarily interested in early-stage, pre-clinical therapeutics companies, and will consider clinical opportunities up to Phase IIa. The firm’s modalities of interests extends beyond antibodies and the firm is also interested in identifying cutting-edge ADCs, biologics, cell therapies, etc. The firm focuses on the following indications: oncology, ophthalmology, nephrology, and bone disorders. The firm will generally not consider opportunities in medical devices, diagnostics, or digital health.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An established group of companies headquartered in Dubai, UAE specializes in the steel and oil industries is run by a family of doctors. Outside of their business in these industries, the firm actively makes direct investments into life science companies in Seed to Series A rounds, and sometimes Series B. Initial average check sizes are between $500k – 1M, though the firm has invested up to $2M. The group does occasionally participate in pre-IPO rounds with larger commitments, but this has been in companies outside of the life sciences industry. In addition, the group is an LP in some micro-VCs that invest in various sectors, and works with them to identify promising co-investment opportunities. The group has mainly considered opportunities in USA and Western Europe, but is open to all companies across the globe with the exception of India, as the group already has a strong network there.

Within life sciences, the firm is most interested in medical device companies and has looked into surgical devices, robotics, etc. The firm is open to all regulatory pathways, but prefers 510k companies. Current areas of interest include elderly care/longevity, genetics, and microbiome. The group will not consider therapeutics or in vitro diagnostics companies; digital health may be considered but is not a high priority.

The group has no specific company or management team requirements. The firm usually acts as a co-investor. The group has a strong hospital network in India as part of their business, and they actively help with the due diligence process.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Boston-based life sciences accelerator founded in 2016 funds, supports and advances life science technologies from early development through clinical proof-of-concept. The accelerator’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The accelerator has access to capital to support companies from seed investment through Series A and B financings through the accelerator and a $210M venture fund. The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the venture fund can invest directly as a Series A investment along with participation in related Series B investments. Lastly, the venture fund is part of some later-stage funds, which can support companies in later-stage private/mezzanine/crossover financings, debt financings, and IPO/follow-on public offerings. The firm is open to global opportunities.

The accelerator and venture fund support opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.). Additionally, open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The accelerator is open to working with all types of management teams, including first time entrepreneurs. The group works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A single family office of Maryland and New Jersey-based family is very flexible in terms of investment size. The group generally looks to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The group prefers A round and later stage companies. Pre-A interest depends upon technology stage. Our preferred geography is North America and Europe.

The group is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics and other immune-directed therapies. The group generally will not consider single target small molecules, biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The pharma is based in Europe. The company forms relationships with early-stage biotech companies, usually structured in the form of rights (worldwide, world excluding US & Japan, or regional rights), co-marketing, or R&D collaborations. The company may also consider participation in equity financing rounds. Recently, the company has entered an agreement to develop an incubator which is expected to open in 2023. The company is open to partnering with companies globally.

Currently, the company focuses on 5 disease areas: oncology, CNS, immune-inflammation (early-stage); cardiovascular disease, and metabolic disease (late-stage).

Within oncology, the company is interested in apoptosis (BCL2 family), novel oncogenes/oncogene stability regulators, epigenetic regulators (with biomarker validation), synthetic lethality associated with genetic defect, stroma/tumor microenvironment, T cell activation, immunosuppression, and innate immunity. In terms of modalities, the firm is primarily looking at small molecules (discovery to early clinical stage) and monoclonal antibodies/bispecifics (early clinical stage).

Within CNS, the firm is looking for small molecules, oligonucleotides, or PROTAC that address rare synucleinopathies, rare tauopathies, repeat expansion diseases, and amyotrophic lateral sclerosis by menas of clearance of toxic proteins and targeted degradation, as well as regulation of transcription and translation of targets. The company is not interested in epilepsy, multiple sclerosis, pain, psychiatry, or infectious diseases, and is currently not seeking antibodies, cell therapy, or vaccines.

Within immuno-inflammatory diseases, the company is most interested in lupus, systemic sclerosis, Sjögren syndrome, and other chronic inflammatory and fibrotic diseases that share similar pathophysiological mechanisms.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a New York-based Life Sciences investment firm. Typical allocations are up to $4M in projects. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach. The firm often syndicates with major US venture capital firms, but it can also lead a financing round. The firm is currently seeking new opportunities in the US and Canada, and Western Europe.

The firm puts 70% focus on therapeutics and 30% on medical devices and diagnostics. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor interest in early-stage breakthrough science with strong management teams. In medical devices, the firm seeks to provide growth funding in de-risked medical devices and diagnostics in final approval steps, launch and international marketing efforts.

The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, health IT, and biosimilars/generics are not of interest. The firm focuses on five key disease areas: oncology, cardiovascular, anti-infectives, CNS/pain, and women’s health. In oncology, the firm seeks therapies with novel mechanisms of action and delivery, human data and signs of efficacy, and it also considers new generation diagnostics technologies. In cardiovascular diseases, the firm seeks life-saving therapies and technologies with strong human data. In anti-infectives, the firm is considering pre-clinical assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.

The firm is looking for high-caliber serial entrepreneurs with unmatched track-record of success and strong credibility. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.